Managing Advanced EGFR-Mutant NSCLC: Expert and Patient Perspectives

Panelists discuss how advanced EGFR-mutant non-small cell lung cancer (NSCLC) requires careful molecular testing and staging for optimal targeted therapy selection, with particular attention to patient demographics and presentation patterns.